Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Yip1 domain family member 3 (YIPF3) is a Golgi-resident transmembrane protein involved in the maintenance of Golgi apparatus structure and acts as a selective autophagy (Golgiphagy) receptor by binding ATG8 family proteins through its cytosolic N-terminal LIR motif, which is regulated by phosphorylation. The YIPF3–YIPF4 complex is essential for targeting Golgi fragments to lysosomes for degradation during autophagy, particularly under starvation. YIPF3 is expressed in various tissues and may also have a role in hematopoiesis and cell differentiation. Mutations or dysfunction in YIPF3 are associated with certain congenital diseases, but there is no evidence it is a current therapeutic target or interacts with drugs[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Yip1 domain family member 3 (YIPF3).